News ‘Remarkable’ ALS Drug May Also Work on Alzheimer’s April 9, 2025 By Ver_ak@va This article is sourced from an external publication. Read the original → ← PreviousAkava Therapeutics, Inc. congratulates SAB Chair Dr. Hande Ozdinler, Founder Dr. Richard B. Silverman, and Dr. William Klein on their recent grant of $7.3 million from the National Institute on Aging to investigate AKV9 in neurodegenerative diseasesNext →Akava Therapeutics, Inc. shares recent data suggesting that AKV9 acts on a common mechanism involved in both Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS)
